People with mesothelioma dont have many treatment options.
A combination of surgery, chemotherapy and radiation is the standard of care. For years, chemotherapy was the only method with approval from the United States Food and Drug Administration.
In 2019, that changed. Now, in 2020 and looking forward, theres a lot of potential for another unorthodox treatment to emerge.
Last May, the FDA approved using the NovoTTF-100L System on a limited basis for pleural mesothelioma. Patients can use the treatment as a first-line option with chemotherapy and only if they arent candidates for surgery.
The NovoTTF-100L became the first mesothelioma treatment option in 15 years to receive FDA approval. In 2004, pemetrexed was approved for treating this cancer.
Hopefully, we wont have to wait another 15 years for the next approval. Here are three classes of cancer treatment that could break through soon and get approval from the FDA.
If youre interested in accessing any of these cancer treatment techniques, please email our registered nurse, Jenna Campagna. She can help you connect with a mesothelioma specialist and look into experimental treatments. Please email her at jenna@mesotheliomaguide.com.
Immunotherapy is at the forefront of many clinical studies involving mesothelioma. The treatment uses drugs to enhance the bodys immune system. The theory is that the body could better fight mesothelioma with just a little outside help.
There are a few variations of immunotherapy. The one used the most in experiments is checkpoint inhibitors. This type of immunotherapy drug targets the relationship between two proteins: PD-1 and PD-L1.
PD-1 is a protein on T-cells, which are the immune systems fighter cells against diseases like mesothelioma. PD-L1 is a protein in mesothelioma cells.
When the two interact, the T-cells cannot detect mesothelioma cells as dangerous to the body. Basically, the PD-1/PD-L1 connection is a mask for mesothelioma.
Checkpoint inhibitors block this connection, which allows the immune system to detect and attack infected cells. The two most common drugs are nivolumab (brand name Opdivo) and pembrolizumab (brand name Keytruda).
Dr. Patrick Forde and his team are testing immunotherapy with surgery and chemotherapy for pleural mesothelioma. Dr. Forde is a thoracic oncologist at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
The clinical trial involves two stages of two immunotherapy drugs: nivolumab and ipilimumab. Patients receive three doses of nivolumab before surgery and one dose of ipilimumab. Then patients can receive further immunotherapy treatment after surgery.
Immunotherapys versatility is one of the treatments best qualities. It can be used before or after surgery, in conjunction with chemotherapy, and even paired with other emerging therapies.
Dr. Forde, who specializes in treating pleural mesothelioma, said immunotherapy can reduce the size of tumors and how widespread they are in the body. This regression can help surgeons remove the diseased cells during operation.
There are numerous forms of gene therapy. One type involves restructuring the genetic characteristics of infected cells. Another type one called suicide gene therapy uses genes to engage the immune system and attack the tumors.
Gene therapy usually isnt sufficient on its own. Instead, its used in conjunction with other mesothelioma treatment options.
The purpose of gene therapy is to repair or weaken infected cells. Repairing can reduce the number of dangerous mesothelioma cells in the body. Weakening can increase the effectiveness of other treatment methods, such as surgery, chemotherapy or immunotherapy.
A Phase 3 clinical trial involving gene therapy might be the most promising one available to pleural mesothelioma patients. Dr. Daniel Sterman is the director of the Multidisciplinary Pulmonary Oncology Program at New York University Langone Health. He is the lead investigator in the study, which combines gene therapy with chemotherapy.
The trial uses TR002, which is adenovirus-delivered Interferon Alpha-2B. The treatment is a gene therapy transported by a virus into the body. Interferon Alpha-2B is a gene therapy that causes tumors to produce interferon alpha, which is a cancer-fighting protein.
The increased production of this protein alerts the immune system of danger. The T-cells recognize that the cells are producing this protein and begin attacking them.
The Phase 2 results were astonishing in a positive way. The disease control rate meaning the cancer either was stagnant or reduced in size was 87.5% for enrolled patients. Additionally, the survival time for patients who received this gene therapy treatment nearly doubled compared to those who didnt.
Virotherapy involves using programmed viruses to either attack mesothelioma cells or kickstart the immune system. Virotherapy also is used as a vessel to transfer other forms of therapy into the body.
Its another outside-the-box method to help the body stop mesotheliomas progression. There are three types of virotherapy used in experimental mesothelioma treatment:
Oncolytic viruses are modified viruses that focus on cancer cells and ignore healthy ones. This form of virotherapy explicitly targets mesothelioma, and its the most common type of the treatment.
Viral vectors are transports for other forms of treatment. Viral vectors could deliver modified genes or an immune system enhancer.
Viral immunotherapy involves using viruses to activate the immune system. Since the viruses are considered intruders, the immune system senses danger and looks for these viruses. Doctors often program the virotherapy similar to the genetic structure of mesothelioma cells. Doing so allows the immune system to identify harmful cells based on these genetic characteristics.
A new clinical trial involving virotherapy and immunotherapy has potential. The study uses ONCOS-102, which is a modified virus that transports immune system stimulants (cytokines).
ONCOS-102 is a combination of viral immunotherapy and oncolytic viruses. The virus aspect breaks apart the mesothelioma cells, and the cytokines send danger signals to the immune systems T-cells. When the mesothelioma cells break apart, they release antigens that the T-cells recognize as cancerous.
This two-pronged process involving virotherapy and immunotherapy has helped patients. Those receiving ONCOS-102 plus chemotherapy had a progression-free survival of around nine months.
Progression-free survival means the patient didnt die and the disease didnt spread further in the body. By comparison, patients who only received chemotherapy had a progression-free survival of around seven months.
Get in depth knowledge about your diagnosis & the best treatments.
Learn More
Continued here:
3 Mesothelioma Treatment Options on the Rise - Mesothelioma Guide
- Krystal Biotech Inc (KRYS) Reports Strong Q4 and Full Year 2023 Financial Results - Yahoo Finance - February 27th, 2024
- New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle - CNBC - February 27th, 2024
- 10 gene therapy companies you should know about - Labiotech.eu - February 27th, 2024
- Former Penn employee sues Gene Therapy Program director, alleging 'unethical and illegal conduct' - The Daily Pennsylvanian - February 27th, 2024
- Gene therapy can't cure deafness because it doesn't need to be cured - The Philadelphia Inquirer - February 27th, 2024
- Fetal surgery expert Tippi MacKenzie shifts to in-utero gene therapy - STAT - February 27th, 2024
- Therapeutic Solutions International Files Patent on Facilitating Effects of JadiCells on Gene Therapy Mediated Cell ... - Business Wire - February 27th, 2024
- CU Anschutz Set to Launch Gene Therapy Trials for Heart Disorder - University of Colorado Anschutz Medical Campus - February 27th, 2024
- ICH targets cell and gene therapies, real-world data as topics ripe for harmonization - Regulatory Focus - February 27th, 2024
- Encoded Therapeutics Announces UK CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101 - Business Wire - February 27th, 2024
- Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in ... - GlobeNewswire - February 27th, 2024
- Therapeutic Solutions International Files Patent on Facilitating Effects of JadiCells on Gene Therapy Mediated Cell ... - The Bakersfield Californian - February 27th, 2024
- Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff - STAT - February 27th, 2024
- Ed Silverman on new gene therapies, biosimilars, coffee, and more - STAT - STAT - February 27th, 2024
- Combatting HIV using gene therapy - Drug Target Review - February 27th, 2024
- NCDHHS working with federal government on increasing access to sickle cell disease treatment - WECT - February 27th, 2024
- Cell Therapy Weekly: FDA Approves First Cell Therapy For Solid Tumors - RegMedNet - February 27th, 2024
- Rejuvenate Bio Announces Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age ... - Business Wire - February 27th, 2024
- New sickle cell therapy uses gene editing at MUSC | Health | postandcourier.com - The Post and Courier - February 27th, 2024
- Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency - Nature.com - February 18th, 2024
- Gene therapy, blood transfusions, stool monitoring: The Sydneysiders trying to escape death - Sydney Morning Herald - February 18th, 2024
- Not too late to repair: gene therapy improves advanced heart failure in animal model - Baylor College of Medicine | BCM - February 18th, 2024
- Direct Administration of CRISPR-Cas9: Tools for Cell and Gene Therapy - Forbes - February 18th, 2024
- Gene therapy's promise seen in its success for AADC deficiency - AADC News - February 18th, 2024
- First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure Treatment - Diagnostic and Interventional Cardiology - February 18th, 2024
- FDA to review expanded use of Sarepta Duchenne gene therapy - Yahoo Finance - February 18th, 2024
- How gene therapy can help treat a rare blood disorder - KUTV 2News - February 18th, 2024
- CRISPR gene therapy Casgevy secures approval in Europe - Pharmaceutical Technology - February 18th, 2024
- FDA Updates for the Week of Feb. 12, 2024: New Approvals, an Extended Review and Goal Dates Set - Managed Healthcare Executive - February 18th, 2024
- First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure - Business Wire - February 18th, 2024
- Lisa Jarvis: A cure for some kinds of hearing loss? Gene therapies are getting closer - St. Paul Pioneer Press - February 18th, 2024
- Spinal Muscular Atrophy Market: Navigating Therapeutic Advances towards USD 5.6 Billion by 2034, with a CAGR of ... - Yahoo Finance - February 18th, 2024
- Crispr Therapeutics' Gene Therapy Wins EU Approval - TipRanks.com - TipRanks - February 18th, 2024
- Revolutionizing Gene Therapy: A Novel Technique for In Vivo CAR T Cells - Medriva - February 18th, 2024
- How Stella Vnook is 'infusing innovation' into cell therapies with Likarda's technology - BioPharma-Reporter.com - February 18th, 2024
- Using cancer's 'superpower' to boost T-cell therapies in mice - FierceBiotech - February 18th, 2024
- Parkinson's Disease Patient Identification and Education Will Need to Improve When New Disease Modifying ... - Yahoo Finance - February 18th, 2024
- CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards? - Yahoo Finance - February 18th, 2024
- Gene Therapy: A Ray of Hope for Heart Failure Treatment | Health News - Medriva - February 18th, 2024
- Gene therapy trials restore hearing to children born deaf - The Hill - February 2nd, 2024
- Early Trial Success for Inherited Deafness Gene-Therapy - RegMedNet - February 2nd, 2024
- Sickle cell gene therapy first focus of Medicaid pay model - Modern Healthcare - February 2nd, 2024
- Beyond chemotherapy: Navigating the promise and perils of CAR-T therapy in pediatric cancer - BioPharma-Reporter.com - February 2nd, 2024
- Angiodema: Gene therapy blocks painful hereditary disorder - BBC - February 2nd, 2024
- FDA: Genome editing therapies may use accelerated approval pathway - Regulatory Focus - February 2nd, 2024
- CRISPR tech treats severe hereditary condition successfully - Interesting Engineering - February 2nd, 2024
- Gene Therapy Restores Hearing in Small Trial for Kids With Hereditary Deafness - Technology Networks - February 2nd, 2024
- Gene-based therapy may slow development of life-threatening heart condition - Medical Xpress - February 2nd, 2024
- Jaguar Gene Therapy Announces FDA Clearance of IND to Study JAG201 in a Genetic Form of Autism Spectrum ... - Business Wire - February 2nd, 2024
- Replacing the PKP2 gene prolongs survival in ARVC patients - Drug Target Review - February 2nd, 2024
- Cell and gene therapies top pharmaceutical industry trend to watch for 2024 - Pharmaceutical Technology - February 2nd, 2024
- Gene Therapy Restores Hearing in Children with Hereditary Deafness - The Hearing Review - February 2nd, 2024
- 2 Dutch among 10 "functionally cured" of hereditary swelling disease by new gene therapy - NL Times - February 2nd, 2024
- FDA publishes final industry guidance for CAR-T and gene therapies - PMLiVE - February 2nd, 2024
- Gene therapy cures hereditary deafness in two people - Advanced Science News - February 2nd, 2024
- Hearing Restored in Deaf Children in Gene Therapy Clinical Trial - Securities.io - February 2nd, 2024
- Vivet Therapeutics Receive 4.9 Million to Advance Development of Gene Therapy - European Pharmaceutical Manufacturer - February 2nd, 2024
- Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on ... - GlobeNewswire - February 2nd, 2024
- Allogene parks Notch CARs, leaving one on the road - FierceBiotech - February 2nd, 2024
- Experimental gene therapy allows kids with inherited deafness to hear - The Associated Press - January 25th, 2024
- Gene-therapy breakthrough allows congenitally deaf children to hear Harvard Gazette - Harvard Gazette - January 25th, 2024
- Gene therapies restore hearing in several kids with inherited deafness - Livescience.com - January 25th, 2024
- Boy born deaf can hear for the first time thanks to a gene therapy procedure - NBC 6 South Florida - January 25th, 2024
- Gene therapy restores hearing in children with hereditary deafness - Medical Xpress - January 25th, 2024
- Children's Hospital of Philadelphia Performs First in U.S. Gene Therapy Procedure to Treat Genetic Hearing Loss - PR Newswire - January 25th, 2024
- Children's Hospital of Philadelphia uses gene therapy to help 11-year-old boy hear for 1st time - WPVI-TV - January 25th, 2024
- Breakthrough gene therapy treatment restores hearing in children born deaf - The Independent - January 25th, 2024
- Gene Therapy Administered Via Virus Cures Deafness in 11-Year-Old Boy - Futurism - January 25th, 2024
- 11-Year-Old Boy Hears For First Time Ever Thanks To Gene Therapy Breakthrough - IFLScience - January 25th, 2024
- Gene Therapy Deafness | National | caledonianrecord.com - The Caledonian-Record - January 25th, 2024
- Sickle cell gene therapy to be covered by Blue Cross insurers - Modern Healthcare - January 25th, 2024
- Experimental gene therapy allows kids with inherited deafness to hear - Jackson Hole News&Guide - January 25th, 2024
- Gene therapy allows 11-year-old boy to hear for the first time - Latest From ITV News - ITVX - January 25th, 2024
- Experimental Gene Therapy Allows Kids With Inherited Deafness To Hear - Southern Minnesota News - January 25th, 2024
- Joint US-China gene therapy trials restore hearing in 5 kids, a first - Interesting Engineering - January 25th, 2024
- Gene Therapy Deafness | Nation | The Daily News - Galveston County Daily News - January 25th, 2024
- In Draft Guidance for Cell and Gene Therapy Industry, FDA Broadens its Approach to Product Potency - Precision Medicine Online - January 25th, 2024
- Gene therapy helps restore hearing in children with hereditary deafness - Shropshire Star - January 25th, 2024
- Gene therapy breakthrough enables deaf boy to hear for the first time - The Week - January 25th, 2024
- FDA eyes collaborative review pilot for gene therapies - Regulatory Focus - January 17th, 2024